pharmaphorum
JANUARY 7, 2021
The European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to post-Brexit drug approval rules. With the UK reeling from one of the worst outbreaks of the disease, it’s a worrying situation for one of the countries worst hit by the pandemic that is relying on vaccines to bring the virus under control.
Pharma Times
JANUARY 4, 2021
KRAS mutations are found in several hard-to-treat cancers
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for ENVARSUS+XR Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. There are seventeen patents protecting this drug. Drug…. The post New patent for Veloxis Pharms drug ENVARSUS XR appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
JANUARY 6, 2021
Throughout the year 2020, pharma marketers were forced to explore new strategies in order to keep up with the many evolving trends. Pharma marketers have quickly learned how to adapt to these trends and are prepared to take on new opportunities in 2021. Five trends that will shape the pharma marketing industry in 2021 include media and tech, location independence, relationships despite digital congestion, questioning systems and doubt in institutions, and feelings around trust and wellness.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JANUARY 8, 2021
The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. Findings of the lab study posted online have not yet been peer reviewed but provide some reassurance for countries like the UK, which are relying on vaccines to bring the pandemic under control.
NY Times
JANUARY 2, 2021
The approvals, which include a shot developed by Bharat Biotech, an Indian pharmaceutical company, begin a vast campaign to inoculate the hard-hit nation’s 1.3 billion people.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Eye on FDA
JANUARY 6, 2021
Each year in January, it is relevant to look back on the activities of FDA during the course of the previous year and look at how it was the same or different from prior years, and to look at trends in new direction. This past year, needless to say was a doozy on all fronts. Let’s begin by looking at approvals. One might have surmised that the advent of the COVID-era might have thrown off new approvals and that NMEs approved would go diminish.
pharmaphorum
JANUARY 6, 2021
Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work. This thought leadership series has been paid and developed by Kite, a Gilead Company. In 2018, we were preparing to build a European facility to produce individualised cell therapies for the treatment of cancer.
Outsourcing Pharma
JANUARY 5, 2021
Industry organizations with hires, promotions, acquisitions and other news to share this month include Parexel, Novartis, WCG, Idifarma and more top firms.
Pharma Times
JANUARY 8, 2021
Anti-inflammatory drugs also accelerated patients' recovery times
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for GOPRELTO Goprelto is a drug marketed by Genus Lifesciences and is included in one NDA. There are six patents protecting this drug. Drug patent litigation…. The post New patent for Genus Lifesciences drug GOPRELTO appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 6, 2021
Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. The logo – which retains the company’s traditional blue colour scheme – has been more than 18 months in the making and according to the company it is “unlocking the pill to reveal Pfizer’s DNA: the power of science.”.
NY Times
JANUARY 8, 2021
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit.
Pharma Times
JANUARY 5, 2021
Company is aiming for approval in the adjuvant setting
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for GOPRELTO Goprelto is a drug marketed by Genus Lifesciences and is included in one NDA. There are six patents protecting this drug. Drug patent litigation…. The post New patent for Genus Lifesciences drug GOPRELTO appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 4, 2021
The pandemic has shed light on inefficiencies in healthcare systems, and provided an opportunity to adjust how we manage care in the future. Jennifer Haas, executive vice president of Noteworth, shares her 2021 predictions surrounding the future of telehealth and big data. . Healthcare providers are grappling with the task of scaling digital care delivery operations for ambulatory patients in response to the cost dynamics of effectively treating large populations with limited resources, especial
Outsourcing Pharma
JANUARY 7, 2021
A leader from the chemical manufacturing firm notes pharma companies are showing increased interest in contracting out their manufacturing functions.
Pharma Times
JANUARY 7, 2021
The prestigious PharmaTimes INTCR competition has amassed a strong following since its introduction over two decades ago, with many of the fantastic finalists eager to show their support.
Drug Patent Watch
JANUARY 7, 2021
This article was originally published by Abdrhman Mahmoud Gamil in World Journal of Advanced Research and Reviews, 2020, 08(03), 337–349 under a Creative Commons Attribution Liscense 4.0. Abstract Procurement is…. The post Pharmaceutical procurement practice aspects appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 8, 2021
How can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector give their thoughts on the key approaches and technologies that are driving patient engagement forward. With COVID-19 presenting new barriers to running and recruiting for clinical trials, making studies patient-centric is more important now than ever before.
Drug Channels
JANUARY 8, 2021
Today’s guest post comes from Julia Phillips, VP of Pharma Accounts and Enablement at CoverMyMeds. Julia discusses common patient access and affordability issues. She describes CoverMyMeds’ technology solutions that are designed to help patients access, afford, and adhere to their prescribed medications. To learn more about CoverMyMeds’ medication access solutions, download their Technology Solutions Overview.
Pharma Times
JANUARY 5, 2021
Key focus of the deal is focal-onset seizure treatment cenobamate
Drug Patent Watch
JANUARY 8, 2021
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Lantheus Medcl drug DEFINITY appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 8, 2021
Six months after rebranding from BHE, Panalgo has won a contract to supply the European Medicines Agency (EMA) with its IHD data analytics platform, pledging to streamline its public health efforts. IHD – or Instant Health Data – will be used by the EMA to carry out data analyses and examine medicinal product utilisation, answer questions about safety and efficacy, and understand how treatments perform in real-world settings, said the Boston, US-based company.
Pharma Mirror
JANUARY 6, 2021
Infant nutrition, outside of breastfeeding, has become a hot topic recently. Families are taking a hard look at how baby formulas’ ingredients impact their children’s health and development. Concerns and Contamination Every day American parents and caregivers reach for over-the-counter baby formulas and are surprised to find chemicals, additives, and other ingredients that are known to cause health concerns.
Pharma Times
JANUARY 4, 2021
Shot was approved by MHRA on 30 December
Drug Patent Watch
JANUARY 8, 2021
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Lantheus Medcl drug DEFINITY appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 8, 2021
New data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus therapies will now be offered routinely to COVID-19 patients in intensive care in the UK. The renaissance of the two therapies comes on the back of the REMAP-CAP trial, which found that the IL-6 inhibitors RoActemra (tocilizumab) and Kevzara (sarilumab) reduced the relative risk of death by 24% when administered to COVID-19 patients within 24 hours of entering intensive care, and reduce the tim
Drug Channels
JANUARY 5, 2021
It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year. Meanwhile, brand-name drug list prices grew at their slowest rate in at least 20 years. See our updated analysis below. I also review the factors behind declining brand-name drug prices. These factors are firmly in place for 2021.
Pharma Times
JANUARY 4, 2021
Submission based on results from phase I CHRYSALIS study
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for COMPLERA Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eleven patents protecting this drug and one…. The post New patent for Gilead Sciences drug COMPLERA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 7, 2021
Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped. Bayer has joined forces with the German biotech to support the development and supply of CVnCoV, an mRNA candidate using a similar technology to the Pfizer/BioNTech and Moderna jabs, with the drugmaker saying it will help CureVac produce “several hundred million doses” CureVac has been working steadily on CVnCoV over the last
Drug Channels
JANUARY 4, 2021
16th Hub and SPP Model Optimization Spring Stakeholder Summit. March 3-5, 2021 | Virtual Event www.informaconnect.com/hub-spp. This important event convenes key stakeholders to showcase innovative hub programs and patient-centric services to maximize access, reimbursement and adherence. Highlighting top-line regulatory actions, updates on the evolving affordability landscape, and industry perspectives on access strategy, this virtual program tackles immediate challenges and delivers actionable,
Pharma Times
JANUARY 7, 2021
Service will accelerate the ethics review stage of clinical trials approval
Drug Patent Watch
JANUARY 6, 2021
Annual Drug Patent Expirations for ERLEADA Erleada is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Janssen Biotech drug ERLEADA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
141 
Let's personalize your content